Pancreatic Ductal Adenocarcinoma
A Study of Abemaciclib (LY2835219) Alone or in Combination with Other Agents in Participants with Previously Treated Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the safety and efficacy of abemaciclib alone and in combination with other drugs versus standard of care in participants with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).
The results of this study are not yet available.
The duration of your participation depends on how well your disease responds to the study treatment and how many cycles of treatment you receive.
Here you can find out a bit more about the requirements for volunteers who took part in this study
- Participant must have histological or cytological diagnosis of ductal adenocarcinoma of the pancreas
- Participant must have adequate organ function
- Participant must not have insulin-dependent diabetes mellitus
- Participant must not have previously received treatment with any cyclin-dependent kinase (CDK) 4 and 6 inhibitor or phosphatidylinositol 3-kinase (PI3K) and/or mammalian target of rapamycin (mTOR) inhibitor